Project

A double-blind randomised phase III trial evaluating the efficacy of ADT +/- darolutamide in de novo metastatic prostate cancer patients with vulnerable functional ability and not elected for docetaxel or androgen receptor targeted agents

Ongoing - recruitment active · 2023 until 2028

Fischer Stefanie, Harder Anja, Quinter Janine